Sunfox Technologies Secures INR 15 Cr in Pre-Series Funding

This brings Sunfox's total capital raised in this round to INR 20 Cr, including a previous INR 5 Cr investment from the USAID through SAMRIDH Health and LetsVenture.

Sunfox Technologies, a health tech startup, has raised INR 15 Cr in a pre-series funding round led by Venture Catalysts. 

The round also saw participation from Finvolve through the IA Growth Opportunities Fund I and Brew Opportunities Fund, along with investments from Universal Group, RP Singhvi Group, and several high-net-worth individuals (HNIs). 

This brings Sunfox's total capital raised in this round to INR 20 Cr, including a previous INR 5 Cr investment from the United States Agency for International Development (USAID) through SAMRIDH Health and LetsVenture.

Strategic Expansion Plans

Sunfox Technologies plans to use the new capital to scale its flagship product, Spandan, both in India and globally. 

Spandan is a smartphone-based portable ECG device that provides 12-lead ECG readings, enabling users to detect heart attacks and monitor cardiac health in real-time. The company aims to make heart health more accessible by bringing this technology into homes and clinics worldwide.

Rajat Jain, CEO, Sunfox Technologies, said, "This capital injection will enable us to scale rapidly, both in India and internationally. It will fuel our growth and bring Spandan into homes and clinics worldwide. We envision a future where heart attacks are as preventable as fevers, with Spandan becoming as ubiquitous as a household thermometer."

About the Funding Round

Venture Catalysts, an integrated incubator and accelerator, has significantly supported Sunfox Technologies. 

Apoorva Ranjan Sharma, co-founder and managing director of Venture Catalysts, commented on the investment and said, "Sunfox represents the future of cardiac care. We are proud partners in their journey and are excited to see them reach new heights with Spandan. Their mission to make heart health accessible globally is truly inspiring, and we believe they are poised to reshape the healthcare landscape.”

Furthermore, Finvolve's participation through the IA Growth Opportunities Fund I and Brew Opportunities Fund and other investors such as Universal Group and RP Singhvi Group underscores the growing interest in Sunfox Technologies' potential to impact cardiac care. 

Operating from Dehradun, a Tier-II city in India, Sunfox Technologies has established an advanced in-house R&D and manufacturing facility. This facility has captured global attention, with interest from prestigious institutions such as Oxford and Wharton. 

Sunfox’s journey has been notable, especially after its Shark Tank India debut, where all five sharks—Namita Thapar, Peyush Bansal, Anupam Mittal, Vineeta Singh, and Ghazal Alagh—decided to invest in the startup.